ClinicalTrials.gg
RecruitingNCT06253858Updated Jun 5, 2026

Ultrasound (US) Guided External Ventricular Catheter Placement

An interventional study of Catheter Placement with Solopass System in Hydrocephalus, sponsored by Milton S. Hershey Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-05.

Sponsored by Milton S. Hershey Medical Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 77 studies in Hydrocephalus with a site in United States — 22 open to participants now, 26 under way, none of them phase 3. Hydrocephalus · United States.

Planned enrollment
34th of 42
10 · median 33
Started
2026
with 5 others
No phase
31 of 77
12 open now
Primary completion
2026-12
later than 10 of 24 live
Registered
60th of 77
by date

Among the 77 studies in Hydrocephalus with a site in United States, this one is the 34th largest by planned enrollment of the 42 interventional ones that give a count, is one of 6 that started in 2026, is one of 31 with no phase, reaches primary completion later than 10 of the 24 other live ones, and was the 60th registered.

Hydrocephalus

190 studies on the registry are indexed under Hydrocephalus; 52 are open to participants now.

Browse Hydrocephalus studies →

Open to participants now

22 of the 77 studies in Hydrocephalus with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Hydrocephalus studies recruiting now, 18 (58%) set no upper age limit and 6 (19%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Hydrocephalus with a site in United States, or all of them as a file.
02

Study summary

To assess the accuracy the SOLOPASS® System US based in the placement of external ventricular drain into the cranial cavity. This study will aim at evaluating the proposed efficacy of the device in targeting the brain ventricles and decrease multiple brain passes, incorrect deployment and malfunctioning of the drain.

03

Conditions studied

  • Hydrocephalus

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Decision made to perform the procedure by the primary consultant
  • Age 18 or older
  • Neuro ICU stay
  • Newly diagnosed hydrocephalus
  • Has a recent CT within the past 24 hrs
  • Normal and coagulation profile
  • No active infection or currently on antibiotics
  • The targeted fluid compartment has more than 50 percent CSF vs blood by CT scan imaging

Exclusion criteria

Exclusion Criteria:

  • Age \<18
  • Not in Neuro ICU setting
  • Previous placement of a ventricular catheter
  • More than 50 percent of the fluid compartment is filled with blood by CT scan
  • Time to include in the trial prohibited by clinical personnel
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Catheter placement with Solopass system

    The Solopass US system will be used during catheter placement procedure to guide the placement of the catheter.

    Device: Catheter Placement with Solopass System

Interventions

  • DeviceCatheter Placement with Solopass System

    This device is used as a guidance for placing a brain catheter to target the brain ventricles and decrease multiple brain passes, incorrect deployment and malfunctioning of the drain.

06

What researchers measure

Primary outcomes

  1. Average number of passes needed to place the catheter in each subject.

    Measured by the number of passes needed to place the catheter. If the first attempt fails, another US sweep will be performed, and another attempt will be performed. If that fails, then the procedure will be aborted.

    Time frame: 0 minutes

Secondary outcomes

  1. Post procedure imaging accuracy of the placement of the EVD will be performed by reviewing post procedure imaging using the Kakarla scoring system

    Grade 1 means optimal placement in the ipsilateral frontal horn or third ventricle; Grade 2 means a functional placement in the contralateral lateral ventricle or no eloquent cortex; and Grade 3 means suboptimal placement in the eloquent cortex or nontarget cerebrospinal fluid space, with or without functional drainage

    Time frame: up to 7 days

Other outcomes

  1. Length of time of the procedure

    Number of minutes necessary to complete the procedure placement of the catheter

    Time frame: Up to three hours

  2. Number of revision

    Quantity of revisions due to the catheter malfunction

    Time frame: up to 7 days

  3. Number of subjects with Cerebrospinal fluid (CSF) infection

    CSF will be collected as part of standard of care after the procedure and tested for infection.

    Time frame: up to 7 days

  4. Number of subjects with Superficial surgical site infection (SSI)

    (The CDC defines SSI as deep and superficial. A superficial incisional SSI is an infection in the area of the skin where the incision was made. A deep incisional SSI occurs beneath the incision area in the muscle and the tissues surrounding the muscles. Signs to be monitored daily and put in a checklist will include redness, pain, unexplained fever source, pain, warmth, pus or swelling.)

    Time frame: up to 7 days

  5. Longevity of the device function

    Number of days until a subsequent catheter is placed

    Time frame: up to 7 days

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Dec 2026, 8 months after the start.

Of 41 interventional studies with no phase under Hydrocephalus, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 63. This study's planned 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2024
First posted
Feb 12, 2024
StartActual
Apr 1, 2026
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06253858
Responsible party
Chris Zacko (Chris Zacko, MD Professor and Vice Chair for Quality, Department of Neurosurgery, Milton S. Hershey Medical Center) — Principal investigator
First posted
Feb 12, 2024
Start date
Apr 1, 2026
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Jun 5, 2026

Study contacts

Sara Craig, MNR, BS
Contact
scraig2@pennstatehealth.psu.edu
717-531-0003 ext. 285799
J C Zacko, MD
principal investigator · Milton S. Hershey Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion